• In the second quarter of 2026, Precigen, Inc. reported revenue of US$54.98 million, net income of US$20.07 million, and diluted earnings per share from continuing operations of US$0.05, a sharp turnaround from the prior year’s loss-making period.
• This profitability was driven largely by rapid uptake of Papsimios, supported by expanded payer coverage to about 315 million US lives and seven-year FDA market exclusivity for adult recurrent respiratory papillomatosis.
• Next, we will examine how Papsimios-driven profitability and broad payer coverage influence Precigen’s investment narrative and future growth assumptions.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Precigen Investment Narrative Recap

To own Precigen today, you need to believe PAPZIMEOS can sustain meaningful, profitable uptake in adult RRP while the company manages its high fixed cost base and limited cash runway. The Q2 2026 jump to US$54.98 million in revenue and US$20.07 million in net income materially strengthens the story around near term profitability, but it does not remove the key risk that demand could slow or reimbursement trends could tighten from here.

The most relevant recent announcement is the long term follow up data for PAPZIMEOS reported in May 2026, showing durable responses in 15 of 18 complete responders and no new safety signals. Together with the seven year FDA market exclusivity and Q2 profitability, this durability data reinforces PAPZIMEOS as the core near term catalyst while also highlighting that future liquidity and margin outcomes still depend heavily on how real world usage and pricing evolve.

Yet investors should also be aware that if real world PAPZIMEOS demand fades faster than expected and fixed costs stay high, Precigen could face...

Precigen's narrative projects $601.1 million revenue and $363.7 million earnings by 2029. This requires 91.4% yearly revenue growth and a $700.4 million earnings increase from -$336.7 million today.

Uncover how Precigen's forecasts yield a $14.50 fair value, a 110% upside to its current price.

Exploring Other Perspectives

Compared with the baseline view, the most optimistic analysts were already assuming revenue could reach about US$622 million and earnings US$374 million by 2029, so after this strong PAPZIMEOS quarter you may find their platform driven growth thesis more appealing or still too aggressive, depending on how confident you are in sustained demand beyond the initial RRP patient pool.

Explore 8 other fair value estimates on Precigen - why the stock might be worth over 4x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Precigen research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Precigen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Precigen's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.